Fjarde AP Fonden Fourth Swedish National Pension Fund Grows Stake in Gilead Sciences, Inc. $GILD

Fjarde AP Fonden Fourth Swedish National Pension Fund raised its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 10.2% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 306,463 shares of the biopharmaceutical company’s stock after acquiring an additional 28,300 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Gilead Sciences were worth $33,978,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of GILD. Smallwood Wealth Investment Management LLC purchased a new stake in shares of Gilead Sciences in the first quarter worth $25,000. Activest Wealth Management grew its stake in shares of Gilead Sciences by 2,837.5% in the first quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 227 shares during the last quarter. GoalVest Advisory LLC lifted its holdings in shares of Gilead Sciences by 7,566.7% during the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 227 shares in the last quarter. Harbor Asset Planning Inc. bought a new position in shares of Gilead Sciences during the second quarter valued at $27,000. Finally, Colonial Trust Advisors lifted its holdings in shares of Gilead Sciences by 304.3% during the first quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 213 shares in the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Stock Down 0.4%

GILD stock opened at $120.47 on Tuesday. Gilead Sciences, Inc. has a fifty-two week low of $86.08 and a fifty-two week high of $124.61. The business’s 50-day moving average is $115.52 and its two-hundred day moving average is $111.21. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. The company has a market cap of $149.48 billion, a price-to-earnings ratio of 24.00, a P/E/G ratio of 0.83 and a beta of 0.34.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating analysts’ consensus estimates of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The company had revenue of $7.08 billion for the quarter, compared to the consensus estimate of $6.95 billion. During the same quarter in the prior year, the company earned $2.01 earnings per share. Gilead Sciences’s revenue was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Insider Transactions at Gilead Sciences

In other news, CEO Daniel Patrick O’day sold 10,000 shares of the firm’s stock in a transaction dated Monday, September 29th. The stock was sold at an average price of $111.66, for a total value of $1,116,600.00. Following the transaction, the chief executive officer owned 591,203 shares of the company’s stock, valued at $66,013,726.98. This trade represents a 1.66% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction dated Wednesday, October 15th. The stock was sold at an average price of $118.08, for a total value of $295,200.00. Following the completion of the transaction, the chief financial officer directly owned 157,055 shares in the company, valued at $18,545,054.40. This trade represents a 1.57% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 61,500 shares of company stock valued at $7,142,140 over the last quarter. 0.27% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on GILD shares. Wolfe Research upped their price target on Gilead Sciences from $135.00 to $140.00 and gave the company an “outperform” rating in a report on Thursday, October 23rd. Daiwa America raised Gilead Sciences from a “hold” rating to a “strong-buy” rating in a report on Tuesday, August 19th. Truist Financial raised Gilead Sciences from a “hold” rating to a “buy” rating and upped their price target for the company from $108.00 to $127.00 in a report on Friday, August 8th. Dbs Bank raised Gilead Sciences to a “moderate buy” rating in a report on Friday, September 5th. Finally, JPMorgan Chase & Co. upped their price target on Gilead Sciences from $135.00 to $145.00 and gave the company an “overweight” rating in a report on Tuesday, September 16th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $122.61.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.